Clinical Trials with Immunotherapy for High-Grade Glioma

Jacob Ruzevick, Christopher Jackson, Jillian Phallen, Michael Lim

Research output: Contribution to journalReview article

Abstract

Immunotherapy is a potential new therapeutic option in patients with high-grade gliomas (HGGs). Phase I/II trials have assessed the efficacy of increasing immune activity using vaccines made from lymphokine-activated killer cells, cytotoxic T cells, autologous tumor cells, or dendritic cells. Studies to decrease tumor immunoresistance have focused on cytokine modulation of known immunosuppressive factors in the tumor microenvironment. Several early studies have reported a survival benefit using different forms of immunotherapy. This article discusses past clinical trials using immunotherapy in HGGs, their efficacy, limits, and biologic and clinical design challenges that must be overcome to advance immunotherapy for patients with HGGs.

Original languageEnglish (US)
Pages (from-to)459-470
Number of pages12
JournalNeurosurgery clinics of North America
Volume23
Issue number3
DOIs
StatePublished - Jul 1 2012

    Fingerprint

Keywords

  • Clinical trials
  • High-grade gliomas
  • Immunotherapy
  • Vaccines

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this